A 47-year-old woman comes to the physician because of easy bruising and fatigue. She appears pale. Her temperature is 38°C (100.4°F). Examination shows a palm-sized hematoma on her left leg. Abdominal examination shows an enlarged liver and spleen. Her hemoglobin concentration is 9.5 g/dL, leukocyte count is 12,300/mm3, platelet count is 55,000/mm3, and fibrinogen concentration is 120 mg/dL (N = 150–400). Cytogenetic analysis of leukocytes shows a reciprocal translocation of chromosomes 15 and 17. Which of the following is the most appropriate treatment for this patient at this time?
Q172
A 51-year-old woman presents to her primary care doctor with diarrhea. She has had 3-10 malodorous and loose bowel movements daily for the last 6 months, though she recalls that her bowel movements started increasing in frequency nearly 2 years ago. She was otherwise healthy until 2 years ago, when she had multiple elevated fasting blood glucose levels and was diagnosed with type 2 diabetes mellitus. She was also hospitalized once 6 months ago for epigastric pain that was determined to be due to cholelithiasis. She is an avid runner and runs 3-4 marathons per year. She is a vegetarian and takes all appropriate supplements. Her body mass index is 19 kg/m^2. She has lost 10 pounds since her last visit 18 months ago. On exam, she has dry mucous membranes and decreased skin turgor. A high-resolution spiral computerized tomography scan demonstrates a 5-cm enhancing lesion in the head of the pancreas. Additional similar lesions are found in the liver. Further laboratory workup confirms the diagnosis. The patient is offered surgery but refuses as she reportedly had a severe complication from anesthesia as a child. This patient should be treated with a combination of octreotide, 5-fluorouracil, and which other medication?
Q173
An investigator is studying the genetic profile of an isolated pathogen that proliferates within macrophages. The pathogen contains sulfatide on the surface of its cell wall to prevent fusion of the phagosome and lysosome. She finds that some of the organisms under investigation have mutations in a gene that encodes the enzyme required for synthesis of RNA from a DNA template. The mutations are most likely to reduce the therapeutic effect of which of the following drugs?
Q174
A 23-year-old woman on prednisone for lupus presents to her primary care physician because she experiences a burning sensation with urination. She has also been urinating more frequently than normal. The patient denies fever, chills, nausea/vomiting, abdominal or back pain, or other changes with urination. Her vital signs and physical exam are unremarkable, and her urine analysis is positive for leukocyte esterase and nitrites. The patient receives a diagnosis and is then prescribed an antimicrobial that acts by inhibiting DNA gyrase. Which adverse effect should the patient be counseled about?
Q175
A 21-year-old male presents after several days of flatulence and greasy, foul-smelling diarrhea. The patient reports symptoms of nausea and abdominal cramps followed by sudden diarrhea. He says that his symptoms started after he came back from a camping trip. When asked about his camping activities, he reports that his friend collected water from a stream, but he did not boil or chemically treat the water. His temperature is 98.6°F (37°C), respiratory rate is 15/min, pulse is 67/min, and blood pressure is 122/98 mm Hg. Stool is sent for microscopy which returns positive for motile protozoans. Which of the following antibiotics should be started in this patient?
Q176
The patient is admitted to the hospital. A stereotactic brain biopsy of the suspicious lesion is performed that shows many large lymphocytes with irregular nuclei. Which of the following is the most appropriate treatment?
Q177
A 55-year-old man presents to his primary care physician for diarrhea. He states that he has experienced roughly 10 episodes of non-bloody and watery diarrhea every day for the past 3 days. The patient has a past medical history of IV drug abuse and recently completed treatment for an abscess with cellulitis. His vitals are notable for a pulse of 105/min. Physical exam reveals diffuse abdominal discomfort with palpation but no focal tenderness. A rectal exam is within normal limits and is Guaiac negative. Which of the following is the best initial treatment for this patient?
Q178
A 21-year-old man presents to the office for a follow-up visit. He was recently diagnosed with type 1 diabetes mellitus after being hospitalized for diabetic ketoacidosis following a respiratory infection. He is here today to discuss treatment options available for his condition. The doctor mentions a recent study in which researchers have developed a new version of the insulin pump that appears efficacious in type 1 diabetics. They are currently comparing it to insulin injection therapy. This new pump is not yet available, but it looks very promising. At what stage of clinical trials is this current treatment most likely at?
Q179
A 48-year-old woman presented to the hospital with a headache, intermittent fevers and chills, generalized arthralgias, excessive thirst, increased fluid intake, and a progressive rash that developed on her back. Three days before seeking evaluation at the hospital, she noticed a small, slightly raised lesion appearing like a spider or insect bite on her back, which she considered to be a scab covering the affected region. The patient's fever reached 39.4°C (102.9°F) 2 days before coming to the hospital, with an intensifying burning sensation on the affected site. When a family member examined the bite, it was noticed that the bump had transformed into a circular rash. The patient took over-the-counter ibuprofen for intense pain so she could sleep through the night. The day before her hospital visit, the patient felt exhausted but managed to complete a normal workday. On the day of the hospital visit, she awoke feeling very ill, with shooting joint pains, high fevers, and excessive thirst, which led to her to seek medical attention. On physical examination, her temperature was 40.1°C (104.2°F), and there was a large circular red rash with a bulls-eye appearance (17 × 19 cm in diameter) on her back. The rest of the physical examination was unremarkable. Her past medical and surgical histories were not significant apart from a history of anaphylaxis when taking a tetracycline. She recalled a walk in the woods 3 weeks before this exam but denied finding a tick or any other ectoparasite on her body. She denied any nutritional or inhalational allergies, although she emphasized that she is allergic to tetracyclines. Based on her symptoms, medical history, and physical examination findings, the attending physician decides to institute antimicrobial therapy immediately. Which antimicrobial drug did the physician prescribe?
Q180
A 25-year-old man comes to the physician because of diarrhea, bloating, nausea, and vomiting for the past 3 days. He describes his stool as soft, frothy, and greasy. He denies seeing blood in stool. The patient went on a hiking trip last week and drank fresh water from the stream. Three months ago, he was on vacation with his family for 2 weeks in Brazil, where he tried many traditional dishes. He also had watery diarrhea and stomach cramping for 3 days during his visit there. He has no history of serious illness. He takes no medications. The patient appears dehydrated. His temperature is 37°C (98.6°F), blood pressure is 100/60 mm Hg, pulse is 80/min, and respirations are 12/min. Examination shows dry mucous membranes and diffuse abdominal tenderness. Microscopy of the stool reveals cysts. Which of the following is the most appropriate next step in management?
Antimicrobials US Medical PG Practice Questions and MCQs
Question 171: A 47-year-old woman comes to the physician because of easy bruising and fatigue. She appears pale. Her temperature is 38°C (100.4°F). Examination shows a palm-sized hematoma on her left leg. Abdominal examination shows an enlarged liver and spleen. Her hemoglobin concentration is 9.5 g/dL, leukocyte count is 12,300/mm3, platelet count is 55,000/mm3, and fibrinogen concentration is 120 mg/dL (N = 150–400). Cytogenetic analysis of leukocytes shows a reciprocal translocation of chromosomes 15 and 17. Which of the following is the most appropriate treatment for this patient at this time?
A. Cyclophosphamide
B. All-trans retinoic acid (Correct Answer)
C. Imatinib
D. Rituximab
E. Platelet transfusion
Explanation: ***All-trans retinoic acid***
- This patient's presentation with **easy bruising, fatigue, pallor, fever, hepatosplenomegaly, thrombocytopenia**, and a **t(15;17) translocation** is highly characteristic of **acute promyelocytic leukemia (APL)**.
- **All-trans retinoic acid (ATRA)** is the cornerstone of APL treatment, inducing differentiation of leukemic promyelocytes and reversing the coagulopathy often associated with this subtype.
*Cyclophosphamide*
- **Cyclophosphamide** is an alkylating agent used in various cancers and autoimmune diseases, but it is **not the primary or most appropriate initial therapy for APL**.
- Its mechanism of action involves DNA damage, which is different from the differentiation-inducing effect needed for APL.
*Imatinib*
- **Imatinib** is a tyrosine kinase inhibitor primarily used for **chronic myeloid leukemia (CML)** and some GISTs, targeting the **BCR-ABL fusion protein**.
- It is **ineffective in APL** as the underlying genetic abnormality (PML-RARA fusion) is different.
*Rituximab*
- **Rituximab** is a monoclonal antibody targeting the **CD20 antigen** found on B-lymphocytes, primarily used for **B-cell non-Hodgkin lymphoma** and some autoimmune conditions.
- It has **no role in the treatment of acute promyelocytic leukemia**, which is a myeloid malignancy.
*Platelet transfusion*
- While the patient has **thrombocytopenia (platelet count 55,000/mm3)** and **easy bruising/hematoma**, suggesting a need for platelet support, it is a **supportive measure**, not the definitive treatment for the underlying disease.
- **Platelet transfusion** alone does not address the fundamental pathophysiology of APL or the associated coagulopathy (fibrinogen 120 mg/dL), which requires ATRA.
Question 172: A 51-year-old woman presents to her primary care doctor with diarrhea. She has had 3-10 malodorous and loose bowel movements daily for the last 6 months, though she recalls that her bowel movements started increasing in frequency nearly 2 years ago. She was otherwise healthy until 2 years ago, when she had multiple elevated fasting blood glucose levels and was diagnosed with type 2 diabetes mellitus. She was also hospitalized once 6 months ago for epigastric pain that was determined to be due to cholelithiasis. She is an avid runner and runs 3-4 marathons per year. She is a vegetarian and takes all appropriate supplements. Her body mass index is 19 kg/m^2. She has lost 10 pounds since her last visit 18 months ago. On exam, she has dry mucous membranes and decreased skin turgor. A high-resolution spiral computerized tomography scan demonstrates a 5-cm enhancing lesion in the head of the pancreas. Additional similar lesions are found in the liver. Further laboratory workup confirms the diagnosis. The patient is offered surgery but refuses as she reportedly had a severe complication from anesthesia as a child. This patient should be treated with a combination of octreotide, 5-fluorouracil, and which other medication?
A. Paclitaxel
B. Glucagon
C. Streptozotocin (Correct Answer)
D. Insulin
E. Methotrexate
Explanation: ***Streptozotocin***
- The patient's presentation with **diarrhea**, **weight loss**, **new-onset diabetes**, and a **pancreatic mass with liver metastases** is highly suggestive of a **neuroendocrine tumor**, specifically a **VIPoma** or **gastrinoma** with potential for glucagonoma given the diabetes. Given the recommended treatment with octreotide and 5-fluorouracil, **streptozotocin** is a key cytotoxic chemotherapy agent used in the treatment of metastatic pancreatic neuroendocrine tumors.
- **Streptozotocin** is an **alkylating agent** that targets pancreatic islet cells and is effective in combination with 5-fluorouracil for advanced, well-differentiated neuroendocrine tumors, especially those that are functional and causing symptoms.
*Paclitaxel*
- **Paclitaxel** is a **microtubule inhibitor** primarily used in breast, ovarian, and lung cancers. It is not a standard chemotherapy agent for pancreatic neuroendocrine tumors in combination with octreotide and 5-fluorouracil.
- While sometimes used in other pancreatic malignancies (e.g., pancreatic adenocarcinoma), it is **not indicated** for the specific context of this neuroendocrine tumor treatment regimen.
*Glucagon*
- **Glucagon** is a hormone that **raises blood glucose levels** and would be contraindicated in a patient with new-onset diabetes and a pancreatic tumor, potentially exacerbating hyperglycemia.
- It is a **hormone**, not a chemotherapy agent, and has no role in treating the underlying pancreatic neuroendocrine tumor.
*Insulin*
- **Insulin** treats hyperglycemia, which is a symptom in this patient due to likely a **glucagonoma** or other neuroendocrine tumor affecting glucose metabolism. However, it does not treat the underlying tumor.
- While necessary for managing diabetes, **insulin** is a supportive treatment and not the chemotherapy agent required to combine with octreotide and 5-fluorouracil for directly targeting the tumor.
*Methotrexate*
- **Methotrexate** is an **antimetabolite** primarily used in various cancers like leukemia, lymphoma, and autoimmune diseases. It is not part of the standard chemotherapy regimen for pancreatic neuroendocrine tumors.
- Its mechanism of action and efficacy profile do not align with the treatment of well-differentiated metastatic pancreatic neuroendocrine tumors in this context.
Question 173: An investigator is studying the genetic profile of an isolated pathogen that proliferates within macrophages. The pathogen contains sulfatide on the surface of its cell wall to prevent fusion of the phagosome and lysosome. She finds that some of the organisms under investigation have mutations in a gene that encodes the enzyme required for synthesis of RNA from a DNA template. The mutations are most likely to reduce the therapeutic effect of which of the following drugs?
A. Pyrazinamide
B. Ethambutol
C. Rifampin (Correct Answer)
D. Streptomycin
E. Levofloxacin
Explanation: ***Rifampin***
- **Rifampin** specifically targets bacterial **DNA-dependent RNA polymerase**, inhibiting **RNA synthesis**. Mutations in the gene encoding this enzyme would directly reduce rifampin's binding and effectiveness.
- The description of the pathogen thriving within macrophages and using **sulfatide to evade lysosomal fusion** strongly suggests **Mycobacterium tuberculosis**, a bacterium for which rifampin is a cornerstone treatment.
*Pyrazinamide*
- **Pyrazinamide** is a prodrug that, once converted to **pyrazinoid acid**, disrupts **mycobacterial membrane potential** and metabolism. Its primary target is not RNA synthesis.
- Its efficacy is pH-dependent and it acts optimally in acidic environments, such as within macrophages, but mutations affecting RNA synthesis would not directly compromise its action.
*Ethambutol*
- **Ethambutol** inhibits **arabinosyl transferase**, an enzyme essential for the synthesis of the **mycobacterial cell wall component arabinogalactan**.
- Its mechanism of action is distinct from RNA synthesis, thus mutations affecting RNA polymerase would not impact its efficacy.
*Streptomycin*
- **Streptomycin** is an **aminoglycoside antibiotic** that binds to the **30S ribosomal subunit**, inhibiting bacterial **protein synthesis**.
- This mechanism is unrelated to DNA-dependent RNA polymerase, so mutations in RNA synthesis enzymes would not affect streptomycin's action.
*Levofloxacin*
- **Levofloxacin** is a **fluoroquinolone antibiotic** that inhibits **bacterial DNA gyrase (topoisomerase II)** and **topoisomerase IV**, thereby blocking DNA replication and transcription.
- While it affects processes related to DNA, its direct target is not the DNA-dependent RNA polymerase enzyme itself, distinguishing it from rifampin's specific mechanism.
Question 174: A 23-year-old woman on prednisone for lupus presents to her primary care physician because she experiences a burning sensation with urination. She has also been urinating more frequently than normal. The patient denies fever, chills, nausea/vomiting, abdominal or back pain, or other changes with urination. Her vital signs and physical exam are unremarkable, and her urine analysis is positive for leukocyte esterase and nitrites. The patient receives a diagnosis and is then prescribed an antimicrobial that acts by inhibiting DNA gyrase. Which adverse effect should the patient be counseled about?
A. Facial redness/flushing
B. Tendon rupture (Correct Answer)
C. Rhabdomyolysis
D. Hemolytic anemia
E. Leukopenia
Explanation: ***Tendon rupture***
- The patient's symptoms (dysuria, frequent urination, positive leukocyte esterase, and nitrites) are consistent with a **urinary tract infection (UTI)**. The antimicrobial that inhibits **DNA gyrase** is a **fluoroquinolone**, and a well-known adverse effect of fluoroquinolones is **tendon rupture**.
- Risk factors for tendon rupture with fluoroquinolones include older age, corticosteroid use, and renal insufficiency, all of which are pertinent to this patient on **prednisone** for lupus.
*Facial redness/flushing*
- This is an adverse effect more commonly associated with drugs like **niacin** or calcium channel blockers, not fluoroquinolones.
- It is generally not a recognized side effect of antibiotics used to treat UTIs.
*Rhabdomyolysis*
- This serious condition involves the breakdown of muscle tissue and is associated with various drugs (e.g., statins, street drugs) and conditions (e.g., trauma, extreme exertion), but not typically fluoroquinolones.
- While muscle pain can occur with fluoroquinolones, severe rhabdomyolysis is rare.
*Hemolytic anemia*
- Certain antibiotics, like sulfonamides or penicillin, can rarely cause drug-induced hemolytic anemia, particularly in patients with **G6PD deficiency**.
- Fluoroquinolones are not commonly associated with hemolytic anemia.
*Leukopenia*
- While some antibiotics can cause bone marrow suppression leading to leukopenia (e.g., chloramphenicol, trimethoprim-sulfamethoxazole), this is not a common or significant adverse effect of fluoroquinolones.
- The patient's underlying lupus and prednisone use might contribute to immune dysregulation, but leukopenia is not the primary concern with fluoroquinolone use.
Question 175: A 21-year-old male presents after several days of flatulence and greasy, foul-smelling diarrhea. The patient reports symptoms of nausea and abdominal cramps followed by sudden diarrhea. He says that his symptoms started after he came back from a camping trip. When asked about his camping activities, he reports that his friend collected water from a stream, but he did not boil or chemically treat the water. His temperature is 98.6°F (37°C), respiratory rate is 15/min, pulse is 67/min, and blood pressure is 122/98 mm Hg. Stool is sent for microscopy which returns positive for motile protozoans. Which of the following antibiotics should be started in this patient?
A. Vancomycin
B. Erythromycin
C. Cephalexin
D. Ciprofloxacin
E. Metronidazole (Correct Answer)
Explanation: ***Metronidazole***
- This patient's symptoms (greasy, foul-smelling diarrhea, flatulence) after consuming untreated stream water are highly suggestive of **Giardiasis**, caused by *Giardia lamblia*.
- **Metronidazole** is the first-line antibiotic for treating Giardiasis due to its efficacy against anaerobic parasites and protozoa.
*Vancomycin*
- **Vancomycin** is primarily used for serious gram-positive bacterial infections, particularly **methicillin-resistant *Staphylococcus aureus* (MRSA)** and *Clostridioides difficile* colitis.
- It has no activity against protozoal infections like Giardiasis.
*Erythromycin*
- **Erythromycin** is a macrolide antibiotic effective against a range of bacterial infections, including atypical pneumonia and certain sexually transmitted infections.
- It is not effective against protozoal parasites.
*Cephalexin*
- **Cephalexin** is a first-generation cephalosporin antibiotic used to treat bacterial infections such as skin and soft tissue infections, strep throat, and urinary tract infections.
- It does not have activity against protozoans.
*Ciprofloxacin*
- **Ciprofloxacin** is a fluoroquinolone antibiotic used for various bacterial infections, including urinary tract infections, gastrointestinal infections (e.g., traveler's diarrhea caused by bacteria), and respiratory tract infections.
- While effective against many bacteria, it is not the primary treatment for protozoal infections like Giardiasis.
Question 176: The patient is admitted to the hospital. A stereotactic brain biopsy of the suspicious lesion is performed that shows many large lymphocytes with irregular nuclei. Which of the following is the most appropriate treatment?
A. Methotrexate (Correct Answer)
B. Pyrimethamine and sulfadiazine
C. Intrathecal glucocorticoids
D. Surgical resection
E. Temozolomide
Explanation: ***Methotrexate***
- A brain biopsy showing **large lymphocytes with irregular nuclei** is highly suggestive of **primary central nervous system lymphoma (PCNSL)**. High-dose methotrexate is the cornerstone of PCNSL treatment due to its ability to cross the **blood-brain barrier** effectively.
- Methotrexate is a **folate antagonist** that inhibits DNA synthesis, making it effective against rapidly dividing cancer cells, including lymphoma cells in the brain.
*Pyrimethamine and sulfadiazine*
- This combination is the standard treatment for **cerebral toxoplasmosis**, an opportunistic infection often seen in immunocompromised patients, which can present as a brain lesion.
- However, the biopsy finding of **lymphoma cells** rules out toxoplasmosis as the primary diagnosis, making this treatment inappropriate.
*Intrathecal glucocorticoids*
- **Glucocorticoids** can be used to reduce **peritumoral edema** and provide symptomatic relief in PCNSL, but they are not a definitive treatment for the lymphoma itself.
- While sometimes used as an adjunct, high-dose glucocorticoids can induce **lymphoma cell apoptosis**, potentially confounding diagnostic biopsy results if administered before the biopsy.
*Surgical resection*
- **Gross total resection** is generally not feasible or recommended for PCNSL because these tumors tend to be multifocal and deeply infiltrating, making complete removal difficult and often associated with significant neurological morbidity.
- The primary treatment for PCNSL is **chemotherapy** (especially high-dose methotrexate) and sometimes radiation, rather than surgery.
*Temozolomide*
- **Temozolomide** is an **oral alkylating agent** primarily used in the treatment of **glioblastoma multiforme** and anaplastic astrocytoma, as well as other high-grade gliomas.
- While it can cross the blood-brain barrier, it is not the primary or most effective chemotherapy for PCNSL, which responds better to methotrexate-based regimens.
Question 177: A 55-year-old man presents to his primary care physician for diarrhea. He states that he has experienced roughly 10 episodes of non-bloody and watery diarrhea every day for the past 3 days. The patient has a past medical history of IV drug abuse and recently completed treatment for an abscess with cellulitis. His vitals are notable for a pulse of 105/min. Physical exam reveals diffuse abdominal discomfort with palpation but no focal tenderness. A rectal exam is within normal limits and is Guaiac negative. Which of the following is the best initial treatment for this patient?
A. Oral rehydration and discharge
B. Vancomycin (Correct Answer)
C. Clindamycin
D. Fidaxomicin
E. Metronidazole
Explanation: ***Vancomycin***
- This patient's recent **antibiotic exposure** (for abscess and cellulitis) combined with **watery diarrhea** (10 episodes/day) and tachycardia (pulse 105/min) strongly suggests **Clostridioides difficile infection (CDI)**.
- **Oral vancomycin** (125 mg PO four times daily × 10 days) is a first-line treatment for initial CDI per current IDSA guidelines and remains the most commonly used agent in clinical practice.
- While fidaxomicin is also first-line (and preferred by guidelines due to lower recurrence rates), vancomycin is more widely available, cost-effective, and equally effective for initial treatment, making it the best initial choice in most clinical settings.
*Oral rehydration and discharge*
- While **oral rehydration** is important for managing dehydration secondary to diarrhea, it is insufficient as the sole treatment given the high clinical suspicion for **CDI**.
- CDI requires targeted antibiotic therapy; discharging with only supportive care risks disease progression, toxic megacolon, and potentially life-threatening complications.
*Clindamycin*
- **Clindamycin** is one of the antibiotics **most strongly associated** with causing **CDI** because it significantly disrupts normal colonic flora.
- Administering clindamycin would worsen the suspected CDI and is absolutely contraindicated in this clinical scenario.
*Fidaxomicin*
- **Fidaxomicin** (200 mg PO twice daily × 10 days) is an excellent antibiotic for **CDI** and is actually recommended as first-line therapy alongside vancomycin in current IDSA guidelines.
- It has advantages including **lower recurrence rates** and better microbiome preservation compared to vancomycin.
- However, in practice, it is less commonly used as initial therapy due to **significantly higher cost** (often >$3,000 vs. <$100 for vancomycin) and more limited availability.
- For exam purposes and typical clinical practice, **vancomycin remains the preferred first-line agent** for initial CDI treatment.
*Metronidazole*
- **Metronidazole** was previously a first-line treatment for **non-severe CDI**, but current IDSA guidelines (2018/2021) no longer recommend it as first-line therapy.
- It has **inferior efficacy** compared to vancomycin and fidaxomicin and is now reserved only for situations where neither vancomycin nor fidaxomicin is available.
- Studies have shown higher treatment failure rates and recurrence rates with metronidazole compared to vancomycin.
Question 178: A 21-year-old man presents to the office for a follow-up visit. He was recently diagnosed with type 1 diabetes mellitus after being hospitalized for diabetic ketoacidosis following a respiratory infection. He is here today to discuss treatment options available for his condition. The doctor mentions a recent study in which researchers have developed a new version of the insulin pump that appears efficacious in type 1 diabetics. They are currently comparing it to insulin injection therapy. This new pump is not yet available, but it looks very promising. At what stage of clinical trials is this current treatment most likely at?
A. Phase 0
B. Phase 2
C. Phase 3 (Correct Answer)
D. Phase 1
E. Phase 4
Explanation: ***Phase 3***
- **Phase 3 trials** involve large-scale studies comparing the new treatment to standard therapy or placebo, often across multiple centers.
- The scenario describes a "new version of the insulin pump" being compared to "insulin injection therapy," indicating a definitive comparison for efficacy and safety against existing treatments.
*Phase 0*
- **Phase 0 trials** are exploratory, small-scale studies (10-15 subjects) using micro-doses to gather preliminary data on pharmacodynamics and pharmacokinetics, not efficacy comparisons.
- They are typically conducted very early in drug development, examining if the drug behaves as expected in humans.
*Phase 2*
- **Phase 2 trials** evaluate the efficacy and further assess safety of a new treatment in a larger group of patients (tens to hundreds).
- While they assess efficacy, they usually don't involve direct comparison with an established standard therapy on the scale implied by the question, which is typically reserved for Phase 3.
*Phase 1*
- **Phase 1 trials** primarily focus on safety, dosage, and side effects in a small group of healthy volunteers or patients with the condition (20-100 subjects).
- These trials are not designed to assess a treatment's efficacy against an existing therapy.
*Phase 4*
- **Phase 4 trials** occur after a drug or device has been approved and marketed, focusing on long-term safety, effectiveness in diverse populations, and new indications.
- The described pump "is not yet available," indicating it has not reached the market and thus is not in Phase 4.
Question 179: A 48-year-old woman presented to the hospital with a headache, intermittent fevers and chills, generalized arthralgias, excessive thirst, increased fluid intake, and a progressive rash that developed on her back. Three days before seeking evaluation at the hospital, she noticed a small, slightly raised lesion appearing like a spider or insect bite on her back, which she considered to be a scab covering the affected region. The patient's fever reached 39.4°C (102.9°F) 2 days before coming to the hospital, with an intensifying burning sensation on the affected site. When a family member examined the bite, it was noticed that the bump had transformed into a circular rash. The patient took over-the-counter ibuprofen for intense pain so she could sleep through the night. The day before her hospital visit, the patient felt exhausted but managed to complete a normal workday. On the day of the hospital visit, she awoke feeling very ill, with shooting joint pains, high fevers, and excessive thirst, which led to her to seek medical attention. On physical examination, her temperature was 40.1°C (104.2°F), and there was a large circular red rash with a bulls-eye appearance (17 × 19 cm in diameter) on her back. The rest of the physical examination was unremarkable. Her past medical and surgical histories were not significant apart from a history of anaphylaxis when taking a tetracycline. She recalled a walk in the woods 3 weeks before this exam but denied finding a tick or any other ectoparasite on her body. She denied any nutritional or inhalational allergies, although she emphasized that she is allergic to tetracyclines. Based on her symptoms, medical history, and physical examination findings, the attending physician decides to institute antimicrobial therapy immediately. Which antimicrobial drug did the physician prescribe?
A. Azithromycin
B. Amoxicillin (Correct Answer)
C. Erythromycin
D. Doxycycline
E. Cephalexin
Explanation: ***Amoxicillin***
- The patient presents with classic symptoms of **Lyme disease**, including a **bull's-eye rash (erythema migrans)**, fever, chills, headache, and arthralgias, following a possible tick exposure.
- Since the patient has a history of **anaphylaxis to tetracyclines**, **amoxicillin** is an appropriate first-line treatment for early Lyme disease in cases where doxycycline is contraindicated, especially in adults.
*Azithromycin*
- While macrolides like azithromycin can be used in some cases of early Lyme disease, they are generally considered **less effective** than doxycycline, amoxicillin, or cefuroxime.
- Its use is typically reserved for patients who cannot tolerate beta-lactams or tetracyclines, and it has shown **lower efficacy** in preventing late-stage manifestations.
*Erythromycin*
- Erythromycin, another macrolide, is **not recommended** as a first-line treatment for Lyme disease due to its **limited efficacy** against *Borrelia burgdorferi*.
- Its use is generally **discouraged** due to higher rates of treatment failure and gastrointestinal side effects compared to other options.
*Doxycycline*
- **Doxycycline** is the **first-line treatment** for early Lyme disease in adults due to its high efficacy against *Borrelia burgdorferi* and its ability to penetrate various tissues.
- However, it is **contraindicated** in this patient due to her history of **anaphylaxis to tetracyclines**.
*Cephalexin*
- **Cephalexin** is a first-generation cephalosporin and is **not effective** against *Borrelia burgdorferi*, the causative agent of Lyme disease.
- Beta-lactams like **cefuroxime axetil** are effective for Lyme disease, but cephalexin specifically is **not recommended** for this condition.
Question 180: A 25-year-old man comes to the physician because of diarrhea, bloating, nausea, and vomiting for the past 3 days. He describes his stool as soft, frothy, and greasy. He denies seeing blood in stool. The patient went on a hiking trip last week and drank fresh water from the stream. Three months ago, he was on vacation with his family for 2 weeks in Brazil, where he tried many traditional dishes. He also had watery diarrhea and stomach cramping for 3 days during his visit there. He has no history of serious illness. He takes no medications. The patient appears dehydrated. His temperature is 37°C (98.6°F), blood pressure is 100/60 mm Hg, pulse is 80/min, and respirations are 12/min. Examination shows dry mucous membranes and diffuse abdominal tenderness. Microscopy of the stool reveals cysts. Which of the following is the most appropriate next step in management?
A. Supportive treatment only
B. Trimethoprim-sulfamethoxazole therapy
C. Ciprofloxacin therapy
D. Metronidazole therapy (Correct Answer)
E. Octreotide therapy
Explanation: ***Metronidazole therapy***
- The patient's symptoms (diarrhea, bloating, greasy stool) and history (drinking stream water, stool cysts) are highly suggestive of **Giardiasis**, for which **metronidazole** is the drug of choice.
- The presence of **cysts in stool microscopy** confirms a parasitic infection, making antibiotic therapy targeting bacteria (like ciprofloxacin or trimethoprim-sulfamethoxazole) inappropriate.
*Supportive treatment only*
- While supportive care (rehydration) is important due to the patient's dehydration, it is **insufficient as the sole management** for Giardiasis given the persistent symptoms and confirmed parasitic infection.
- Delaying specific antiparasitic treatment can lead to **chronic symptoms** and malabsorption.
*Trimethoprim-sulfamethoxazole therapy*
- This antibiotic is effective against certain **bacterial infections**, but it is generally *not* the first-line treatment for **Giardiasis**.
- Its use would be more appropriate for specific bacterial diarrheas or other parasitic infections like *Cystoisospora* or *Cyclospora*.
*Ciprofloxacin therapy*
- **Ciprofloxacin** is a fluoroquinolone antibiotic primarily used for **bacterial diarrheas**, particularly those caused by *E. coli*, *Salmonella*, or *Shigella*.
- It is **ineffective** against **Giardia** and would not treat the underlying parasitic infection.
*Octreotide therapy*
- **Octreotide** is a somatostatin analog used to treat **secretory diarrhea**, often associated with neuroendocrine tumors (e.g., VIPomas) or refractory diarrhea in AIDS patients.
- It has **no role** in treating infectious parasitic diarrhea like **Giardiasis**.
